FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013373443> ?p ?o ?g. }

• W2013373443 endingPage "130" @default.
• W2013373443 startingPage "130" @default.
• W2013373443 abstract "Enhancing the graft versus tumor (GvT) effect without graft versus host disease (GvHD) is critical to the success of reduced intensity (RIC) strategies for allogeneic transplantation. Despite establishing donor lymphohematopoiesis, relapse rates remain high. Standard DLI given at relapse or prophylactically to enhance donor chimerism has met with limited success in improving transplant outcomes. Co-stimulation of donor T-cells, using anti-CD3/CD28 coated beads to serve as artificial APCs, may reverse functional T cell tolerance, thereby restoring immune responsiveness and potentiate GVT. Unlike standard DLI, ex vivo co-stimulation may enhance T cell activity by removing and activating T cells outside of a tumor-induced immunosuppressive milieu. We report the preliminary results of a feasibility trial of ex vivo co-stimulated DLI from sibling and unrelated donors given ‘prophylactically’ at 4 and 6 months after RIC allogeneic transplantation for patients (pts) with high-risk hematologic malignancy. Methods: 15 pts have undergone RIC with alemtuzumab, Fludarabine,Busulfan with peripheral blood stem cell transplantation (PBSCT) and planned activated DLI (pADLI) at 4 months (1 × 107 CD3+/kg) and 6 months (1 × 108 CD3+/kg) post-transplant in the absence of GvHD or relapse. All pts received tacrolimus and methotrexate as GvHD prophylaxis. Results: 8 pts (AML, n = 6; ALL CR1 n = 2) received grafts from HLA-identical sibling donors, 7 (AML n = 5; MDS n = 1; ALL, n = 1) from matched unrelated donors. Donor hematopoiesis was established in all patients. Of the 11 infusions given to date, there has been no infusion-related toxicity, confirming the safety and feasibility of this strategy. 8 pts have received the first of 2 planned infusions of pADLI. Of the remaining 7 pts, 4 infusions are upcoming, 1 was precluded by early relapse, and 2 were precluded by early NRRM. Of the 8 pts who received their initial pADLI#1, 3 have received a second infusion. 5 pts did not receive pADLI#2 because of relapse (n = 3), GvHD (n = 1), and transient uveitis in the absence of GvHD (n = 1). Overall incidence of acute GvHD (aGvHD) has been low; 1 pt developed aGvHD prior to pADLI#1, and 1 pt developed aGvHD after pADLI #1. No patient has developed chronic GvHD. Conclusion: Preliminary results of this trial demonstrates that RIC with PBSCT followed by ex vivo costimulated pADLI for poor prognosis hematologic malignancies is safe and feasible with potential for enhancing GvT without increasing GvHD." @default.
• W2013373443 created "2016-06-24" @default.
• W2013373443 creator A5008558372 @default.
• W2013373443 creator A5014838335 @default.
• W2013373443 creator A5016205416 @default.
• W2013373443 creator A5029801761 @default.
• W2013373443 creator A5029979708 @default.
• W2013373443 creator A5037460404 @default.
• W2013373443 creator A5040440615 @default.
• W2013373443 creator A5041976525 @default.
• W2013373443 creator A5047973111 @default.
• W2013373443 creator A5089409657 @default.
• W2013373443 creator A5090096125 @default.
• W2013373443 date "2009-02-01" @default.
• W2013373443 modified "2023-09-24" @default.
• W2013373443 title "Prophylactic Administration Of Ex VIVO Co-Stimulated Donor Lymphocyte Infusion (DLI) From Related And Unrelated Donors After Reduced Intensity Conditioning For High Risk Hematologic Malignancies" @default.
• W2013373443 doi "https://doi.org/10.1016/j.bbmt.2008.12.398" @default.
• W2013373443 hasPublicationYear "2009" @default.
• W2013373443 type Work @default.
• W2013373443 sameAs 2013373443 @default.
• W2013373443 citedByCount "0" @default.
• W2013373443 crossrefType "journal-article" @default.
• W2013373443 hasAuthorship W2013373443A5008558372 @default.
• W2013373443 hasAuthorship W2013373443A5014838335 @default.
• W2013373443 hasAuthorship W2013373443A5016205416 @default.
• W2013373443 hasAuthorship W2013373443A5029801761 @default.
• W2013373443 hasAuthorship W2013373443A5029979708 @default.
• W2013373443 hasAuthorship W2013373443A5037460404 @default.
• W2013373443 hasAuthorship W2013373443A5040440615 @default.
• W2013373443 hasAuthorship W2013373443A5041976525 @default.
• W2013373443 hasAuthorship W2013373443A5047973111 @default.
• W2013373443 hasAuthorship W2013373443A5089409657 @default.
• W2013373443 hasAuthorship W2013373443A5090096125 @default.
• W2013373443 hasBestOaLocation W20133734431 @default.
• W2013373443 hasConcept C126322002 @default.
• W2013373443 hasConcept C143998085 @default.
• W2013373443 hasConcept C150903083 @default.
• W2013373443 hasConcept C203014093 @default.
• W2013373443 hasConcept C207001950 @default.
• W2013373443 hasConcept C26291073 @default.
• W2013373443 hasConcept C2776694085 @default.
• W2013373443 hasConcept C2776755627 @default.
• W2013373443 hasConcept C2777408962 @default.
• W2013373443 hasConcept C2779015954 @default.
• W2013373443 hasConcept C2779263901 @default.
• W2013373443 hasConcept C2779695342 @default.
• W2013373443 hasConcept C2779972918 @default.
• W2013373443 hasConcept C2780611847 @default.
• W2013373443 hasConcept C2911091166 @default.
• W2013373443 hasConcept C71924100 @default.
• W2013373443 hasConcept C86803240 @default.
• W2013373443 hasConcept C90924648 @default.
• W2013373443 hasConceptScore W2013373443C126322002 @default.
• W2013373443 hasConceptScore W2013373443C143998085 @default.
• W2013373443 hasConceptScore W2013373443C150903083 @default.
• W2013373443 hasConceptScore W2013373443C203014093 @default.
• W2013373443 hasConceptScore W2013373443C207001950 @default.
• W2013373443 hasConceptScore W2013373443C26291073 @default.
• W2013373443 hasConceptScore W2013373443C2776694085 @default.
• W2013373443 hasConceptScore W2013373443C2776755627 @default.
• W2013373443 hasConceptScore W2013373443C2777408962 @default.
• W2013373443 hasConceptScore W2013373443C2779015954 @default.
• W2013373443 hasConceptScore W2013373443C2779263901 @default.
• W2013373443 hasConceptScore W2013373443C2779695342 @default.
• W2013373443 hasConceptScore W2013373443C2779972918 @default.
• W2013373443 hasConceptScore W2013373443C2780611847 @default.
• W2013373443 hasConceptScore W2013373443C2911091166 @default.
• W2013373443 hasConceptScore W2013373443C71924100 @default.
• W2013373443 hasConceptScore W2013373443C86803240 @default.
• W2013373443 hasConceptScore W2013373443C90924648 @default.
• W2013373443 hasIssue "2" @default.
• W2013373443 hasLocation W20133734431 @default.
• W2013373443 hasOpenAccess W2013373443 @default.
• W2013373443 hasPrimaryLocation W20133734431 @default.
• W2013373443 hasRelatedWork W1955322177 @default.
• W2013373443 hasRelatedWork W1994441257 @default.
• W2013373443 hasRelatedWork W1995219753 @default.
• W2013373443 hasRelatedWork W2060940696 @default.
• W2013373443 hasRelatedWork W2066644843 @default.
• W2013373443 hasRelatedWork W2549238304 @default.
• W2013373443 hasRelatedWork W2552987542 @default.
• W2013373443 hasRelatedWork W2743113491 @default.
• W2013373443 hasRelatedWork W2983241787 @default.
• W2013373443 hasRelatedWork W4322486761 @default.
• W2013373443 hasVolume "15" @default.
• W2013373443 isParatext "false" @default.
• W2013373443 isRetracted "false" @default.
• W2013373443 magId "2013373443" @default.
• W2013373443 workType "article" @default.